2024-05-15T13:16:15-05:00 2023-06-30 320530003 QUIGLEY & MIRON 3550 WILSHIRE BLVD 1660 LOS ANGELES CA 90010 990 2022-07-01 813132011 MEDTECH INNOVATOR MEDT 7074666887 907 WESTWOOD BLVD 1067 LOS ANGELES CA 90024 PAUL GRAND CEO/PRESIDENT 7074666887 2024-05-15 PAUL GRAND 999009999 0 ARMEN GRIGORIAN P01582463 2136393550 2 AAL1 IAL1 2022 2023-04-26 12:10:37Z PAUL GRAND 907 WESTWOOD BLVD 1067 LOS ANGELES CA 90024 13316576 0 X MEDTECHINNOVATOR.ORG X 2016 CA MEDTECH INNOVATOR ORGANIZES AND RUNS A GLOBAL COMPETITION AND VIRTUAL ACCELERATOR FOR MEDICAL DEVICE, DIGITAL HEALTH, AND DIAGNOSTIC STARTUP COMPANIES. 4 3 19 500 0 0 3463152 13316576 0 0 0 0 0 0 3463152 13316576 972000 826500 0 0 1905222 2268352 0 0 133707 660689 849402 3537911 3944254 -74759 9372322 5483836 14756217 335883 235942 5147953 14520275 X MEDTECH INNOVATOR ORGANIZES AND RUNS A GLOBAL COMPETITION AND VIRTUAL ACCELERATOR FOR MEDICAL DEVICE, DIGITAL HEALTH, AND DIAGNOSTIC STARTUP COMPANIES. 0 0 3482701 826500 MEDTECH INNOVATOR ("MTI") IS THE LARGEST HEALTH CARE ACCELERATOR IN THE WORLD. ITS MISSION IS TO IMPROVE THE LIVES OF PATIENTS BY ACCELERATING THE GROWTH OF COMPANIES THAT ARE TRANSFORMING THE HEALTH CARE SYSTEM. WHILE MANY ENTITIES EXIST THAT PROVIDE EARLY-STAGE SUPPORT FOR HEALTH CARE INNOVATION, THESE ORGANIZATIONS COMMONLY ARE REGIONALLY-BASED AND LIMITED BY THE FINANCIAL RESOURCES AND EXPERTISE OF THEIR LOCAL ECOSYSTEMS. AS A RESULT, PROMISING MEDICAL INNOVATIONS RECEIVE EARLY SUPPORT BUT ULTIMATELY FAIL TO REACH PATIENTS. MTI HAS BEEN PURPOSE-BUILT TO IDENTIFY THE MOST VIABLE STARTUPS AND IMMERSE THEM IN THE BEST VIRTUAL MEDTECH ECOSYSTEM IN THE WORLD, NO MATTER WHERE THEY ARE BASED. MTI PROVIDES A RESOURCE-RICH ENVIRONMENT TO ASSIST STARTUPS IN HONING THEIR BUSINESS MODELS, DEVELOPING THEIR VALUE PROPOSITIONS, AND SECURING THEIR NEXT ROUND OF FUNDING, AMONG OTHER CHALLENGES FACED BY COMPANIES ATTEMPTING TO COMMERCIALIZE INNOVATIVE HEALTH TECHNOLOGY FOR THE BENEFIT OF PATIENTS AROUND THE WORLD. MTI'S FLAGSHIP PROGRAM SUPPORTS MEDICAL DEVICE, DIGITAL HEALTH, AND DIAGNOSTIC STARTUPS AND SCALE-UPS. IN 2021, MTI LAUNCHED BIOTOOLS INNOVATOR, A NEW INITIATIVE THAT LEVERAGES ITS SUCCESSFUL MODEL TO SUPPORT INNOVATORS IN THE LIFE SCIENCE TOOLS AND DIAGNOSTICS SPACES. 1.MTI UNDERTAKES TWO PRIMARY ACTIVITIES: SECTOR/REGIONAL-BASED COMPETITIONS FOR INNOVATIVE STARTUPS AND A FOUR-MONTH MENTORSHIP-DRIVEN ACCELERATOR FOR THE LEADING APPLICANTS. EACH YEAR, MTI GIVES OUT A COMBINATION OF CASH PRIZES AND IN-KIND AWARDS THROUGH ITS VARIOUS COMPETITIONS, WHICH INCLUDE SEVERAL ROUNDS DURING WHICH THOUSANDS APPLY AND HUNDREDS OF COMPANIES GAIN INCREASING AMOUNTS OF EXPOSURE TO INDUSTRY LEADERS THROUGH ONLINE APPLICATION REVIEWS, IN-PERSON AND VIRTUAL PITCH EVENTS, AND AUDIENCE-DRIVEN, PUBLIC COMPETITIONS IN PARTNERSHIP WITH LEADING INDUSTRY CONFERENCES.AS THE COMPETITION PROGRESSES, COMPANIES ARE ACCEPTED INTO THE ANNUAL COHORT. THESE STARTUPS GAIN CRITICAL INDUSTRY-WIDE VISIBILITY AND ACCESS TO LEADING INVESTORS, MANUFACTURERS, PROVIDERS, AND CUSTOMERS. AMONG MANY BENEFITS, THEY RECEIVE EXCLUSIVE NETWORKING OPPORTUNITIES, INTERACTIVE WORKSHOPS, AND COACHING. THE COMPANIES ALSO HAVE MULTIPLE OCCASIONS TO SHOWCASE THEIR PRODUCTS AND GAIN EXPERIENCE PITCHING TO AUDIENCES OF INDUSTRY STAKEHOLDERS AND DECISION-MAKERS. A SUBSET OF EARLIER-STAGE COMPANIES TAKE PART IN A CUSTOMIZED MENTORSHIP PROGRAM WHERE THEY ARE PAIRED WITH SENIOR LEADERS IN THE MEDICAL TECHNOLOGY (MEDTECH) OR LIFE SCIENCES INDUSTRIES. ALL COHORT COMPANIES HAVE THE OPPORTUNITY TO COMPETE FOR NON- DILUTIVE CASH PRIZES AND IN-KIND AWARDS.2.MTI HAS ATTRACTED TOP TALENT TO OVERSEE THE COMPETITION AND ACCELERATOR PROGRAMS, INCLUDING STAFF MEMBERS WITH ADVANCED DEGREES AND DOCTORATES IN FIELDS OF STUDY RELEVANT TO THE STARTUP COMPANIES THEY ASSIST. MTI STAFFERS HAVE A BROAD KNOWLEDGE AND UNDERSTANDING OF THE MEDICAL TECHNOLOGY AND LIFE SCIENCES INDUSTRIES, INCLUDING THE REGULATORY AND REIMBURSEMENT REQUIREMENTS, THE INVESTMENT ENVIRONMENT, AND THE CLINICAL AND SCIENTIFIC NEEDS FOR RESEARCH AND DEVELOPMENT.MTI ALSO DEVELOPS RELATIONSHIPS WITH HUNDREDS OF INDUSTRY EXECUTIVES, HEALTH CARE PROVIDERS, INVESTORS AND KEY OPINION LEADERS, FOR THE BENEFIT OF COMPANIES PARTICIPATING IN ITS COMPETITION AND ACCELERATOR. MTI BRINGS THESE EXPERTS TOGETHER TO SERVE AS APPLICATION REVIEWERS AND JUDGES AT REGIONAL PITCH EVENTS AND COMPETITIONS, AND THEY OFFER FEEDBACK, GUIDANCE AND MENTORSHIP TO COMPANIES THAT PROGRESS THROUGH THE PROGRAM. THESE EXPERTS VOLUNTEER THEIR TIME TO SUPPORT MTI IN ITS MISSION TO IMPROVE THE LIVES OF PATIENTS.3.THE EVENTS OF THE COMPETITION ARE CONDUCTED THROUGHOUT THE YEAR, WITH APPLICATIONS OPENING IN THE FALL SEASON OF THE PRECEDING YEAR.THE ACCELERATOR PROGRAMS TYPICALLY RUN FROM JUNE THROUGH OCTOBER.4.THE EVENTS OF THE COMPETITION AND ACCELERATOR TAKE PLACE VIRTUALLY AND IN CITIES AROUND THE UNITED STATES, SUCH AS SAN FRANCISCO, LOS ANGELES, SAN DIEGO, BOSTON, PHILADELPHIA, AND WASHINGTON, D.C., AND IN INTERNATIONAL LOCATIONS SUCH AS IRELAND AND SINGAPORE.THE ACCELERATOR IS A VIRTUAL PROGRAM, LARGELY CONDUCTED VIA WEBINAR AND TELECONFERENCE, IN ADDITION TO MULTI-DAY, IN-PERSON EVENTS HELD AT ITS BEGINNING AND CONCLUSION. ALL OF THE COMPANIES SELECTED FOR MEDTECH INNOVATOR'S ANNUAL COHORT PARTICIPATE IN THE INNOVATOR SUMMIT AND FINALS, WHICH BRING TOGETHER SENIOR LEADERSHIP FROM EACH COMPANY ALONG WITH REPRESENTATIVES FROM MEDTECH INNOVATOR'S CORPORATE PARTNERS, REPRESENTATIVES FROM FEDERAL AGENCIES THAT SUPPORT MEDICAL INNOVATION SUCH AS FDA, HHS, DOD, AND NIH, AND KEY STAKEHOLDERS SUCH AS INVESTORS AND HEALTH CARE PROVIDERS.5.MTI SEEKS TO IMPROVE THE LIVES OF PATIENTS BY ACCELERATING THE GROWTH OF STARTUP COMPANIES THAT ARE TRANSFORMING THE HEALTH CARE SYSTEM. THIS WILL BE ACCOMPLISHED BY OFFERING SUBSTANTIVE RESOURCES AND NETWORK CONNECTIONS TO THE STARTUPS LEADING UP TO AND DURING THE ACCELERATOR AS WELL AS PROVIDING DIRECT FUNDING TO SELECT COMPANIES THROUGH AWARDS IN THE COMPETITION. MTI'S ACTIVITIES FURTHER THE PUBLIC GOOD BY UNITING LEADING STAKEHOLDERS IN THE MEDTECH INNOVATION ECOSYSTEM TO SUPPORT AND GUIDE TRANSFORMATIVE EARLY-STAGE COMPANIES THAT ARE STRIVING TO SOLVE UNMET PATIENT NEEDS AND INCREASE EFFICIENCY, QUALITY, EQUITY AND VALUE IN THE HEALTH CARE SYSTEM. 6.MTI IS FUNDED BY CORPORATE INDUSTRY DONORS, INCLUDING LEADING MANUFACTURERS, PRIVATE FOUNDATIONS, INVESTORS, SERVICE PROVIDERS, STATE AND FEDERAL TRADE ASSOCIATIONS, AND GRANTS FROM GOVERNMENTAL AGENCIES. MTI HOPES TO INCREASE FINANCIAL SUPPORT FROM GOVERNMENTAL AGENCIES, TRADE ASSOCIATIONS, AND PRIVATE FOUNDATIONS THAT SUPPORT HEALTH CARE INNOVATION, AS MTI PROVIDES A UNIQUE FRAMEWORK TO HELP ENSURE THAT IMPORTANT GRANT-SUPPORTED HEALTH CARE TECHNOLOGIES ACTUALLY REACH PATIENTS IN NEED.7.THERE CURRENTLY ARE NO DBAS. MTI'S WEBSITE IS HTTPS://MEDTECHINNOVATOR.ORG. 3482701 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 0 1 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 7 0 19 1 0 0 0 0 0 0 0 0 0 0 0 0 X 4 3 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 CA X THE ORGANIZATION 3108241700 907 WESTWOOD BLVD 1067 LOS ANGELES CA 90024 CHRISTOPHER MARTIN DIRECTOR 3.00 X 0 0 0 SCOTT WHITAKER DIRECTOR 2.00 X 0 0 0 PAUL GRAND CEO & PRESIDENT 50.00 X X 756144 0 53470 BIREN MEHTA DIRECTOR 2.00 X 0 0 0 KATHRYN ZAVALA COO 50.00 X 295000 0 20085 BRIAN BENSON VP, STRATEGIC ALLIANCES 50.00 X 0 201250 29443 AYELET MAROM VP, PROGRAMS 50.00 X 0 138650 17934 1051144 339900 120932 2 0 1 0 0 371294 12945282 13316576 13316576 0 0 0 717000 717000 109500 109500 1429616 1202809 142962 83845 608613 521494 62507 24612 25290 21675 2578 1037 104738 89494 10626 4618 100095 84732 10095 5268 49570 49570 22055 22055 31650 26792 3192 1666 89271 75568 9004 4699 119380 101057 12040 6283 2167 1835 218 114 16494 13962 1664 868 EVENTS VENUES AND PRODU 505578 505578 MEALS AND ENTERTAINMENT 13237 11205 1335 697 3944254 3482701 327846 133707 2338780 2575152 3143389 11722305 449555 11789 2584 1667 9205 5483836 14756217 112181 235942 223702 0 335883 235942 X 1958410 2475190 3189543 12045085 5147953 14520275 5483836 14756217 9372322 0 X X 0 0 0 X 3061804 3417724 4582114 3463152 13316576 27841370 3061804 3417724 4582114 3463152 13316576 27841370 16953522 10887848 2610 1089 3699 27845069 185 0.39100 0.54760 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 11789 2584 9205 9205 X PART X, LINE 2: ACCOUNTING STANDARDS REQUIRE AN ORGANIZATION TO EVALUATE ITS TAX POSITIONS AND PROVIDE FOR A LIABILITY FOR ANY POSITIONS THAT WOULD NOT BE CONSIDERED "MORE LIKELY THAN NOT" TO BE UPHELD UNDER A TAX AUTHORITY EXAMINATION. MANAGEMENT HAS EVALUATED ITS TAX POSITIONS AND HAS CONCLUDED THAT A PROVISION FOR A TAX LIABILITY IS NOT NECESSARY AT JUNE 30, 2023. GENERALLY, THE ORGANIZATION'S INFORMATION RETURNS REMAIN OPEN FOR EXAMINATION THREE (FEDERAL) OR FOUR (STATE OF CALIFORNIA) YEARS FROM THE DATE OF FILING. 0 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM 0 0 PROGRAM SERVICES MEETINGS AND EVENTS 30000 NORTH AMERICA 0 0 GRANTS PRIZE MONEY FOR MEDICAL INNOVATION 14500 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 GRANTS PRIZE MONEY FOR MEDICAL INNOVATION 109500 0 0 0 0 0 0 154000 0 154000 NORTH AMERICA PRIZE MONEY FOR MEDICAL INNOVATION 10000 BANK WIRE 0 EUROPE (INCLUDING ICELAND & GREENLAND) PRIZE MONEY FOR MEDICAL INNOVATION 10000 BANK WIRE 0 EUROPE (INCLUDING ICELAND & GREENLAND) PRIZE MONEY FOR MEDICAL INNOVATION 25000 BANK WIRE 0 EUROPE (INCLUDING ICELAND & GREENLAND) PRIZE MONEY FOR MEDICAL INNOVATION 25000 BANK WIRE 0 EUROPE (INCLUDING ICELAND & GREENLAND) PRIZE MONEY FOR MEDICAL INNOVATION 10000 BANK WIRE 0 EUROPE (INCLUDING ICELAND & GREENLAND) PRIZE MONEY FOR MEDICAL INNOVATION 25000 BANK WIRE 0 0 0 0 0 0 0 PART I, LINE 3: THE ACCRUAL BASED METHOD ACCOUNTING WAS USED TO ACCOUNT FOR EXPENDITURES PART III ACCOUNTING METHOD: 1 GENNEXT TECHNOLOGIES 248 MAIN STREET SUITE 100 HALF MOON BAY CA 94019 010854186 250000 0 PRIZE MONEY FOR MEDICAL INNOVATION CELL CHORUS 5000 GULF FWY BLDG 4 RM 118 HOUSTON TX 77023 822808222 10000 0 PRIZE MONEY FOR MEDICAL INNOVATION DROP GENIE 68 HARRISON AVENUE BOSTON MA 02111 833830125 10000 0 PRIZE MONEY FOR MEDICAL INNOVATION REALSEQ BIOSCIENCES 2125 DELAWARE AVE SUITE B SANTA CRUZ CA 95060 834428925 10000 0 PRIZE MONEY FOR MEDICAL INNOVATION EVOENDO 12649 E CALEY AVENUE 116 CENTENNIAL CO 80111 822730022 10000 0 PRIZE MONEY FOR MEDICAL INNOVATION PHIEX TECHNOLOGIES ONE BOSTON PLACE BOSTON MA 02108 851088452 350000 0 PRIZE MONEY FOR MEDICAL INNOVATION SAFEBEAT 900 FORTRESS STREET SUITE 190 DPT 17118 CHICO CA 95973 863933762 12500 0 PRIZE MONEY FOR MEDICAL INNOVATION LIMAX BIOSCIENCES 519 SOMERVILLE AVENUE 257 SOMERVILLE MA 02143 873099500 37500 0 PRIZE MONEY FOR MEDICAL INNOVATION STROKEDX 271 S CHESTER AVENUE PASADENA CA 91106 874724805 10500 0 PRIZE MONEY FOR MEDICAL INNOVATION JUNEBRAIN INC 875 HOLLINS STREET SUITE 102 BALTIMORE MD 21201 842636016 5500 0 PRIZE MONEY FOR MEDICAL INNOVATION 10 PART I, LINE 2: COMPETITION ATTENDEES VOTE ON PRIZE WINNERS BASED ON MEDICAL INNOVATIONS PRESENTED. X X X 0 0 0 0 0 0 0 0 0 PAUL GRAND CEO & PRESIDENT 756144 0 0 0 0 0 0 0 53470 0 809614 0 0 0 KATHRYN ZAVALA COO 295000 0 0 0 0 0 0 0 20085 0 315085 0 0 0 BRIAN BENSON VP, STRATEGIC ALLIANCES 0 201250 0 0 0 0 0 0 0 29443 0 230693 0 0 AYELET MAROM VP, PROGRAMS 0 138650 0 0 0 0 0 0 0 17934 0 156584 0 0 FORM 990, PART VI, SECTION B, LINE 11B THE BOARD OF DIRECTORS REVIEWS THE FORM 990 PRIOR TO FILING THE RETURN. FORM 990, PART VI, SECTION B, LINE 12C BOARD MEMBERS ARE REQUIRED ANNUALLY TO REVIEW AND SIGN A CONFLICT OF INTEREST DISCLOSURE STATEMENT. THE ORGANIZATION'S CONFLICT OF INTEREST POLICY REQUIRES THAT A TRUSTEE SHALL EXCUSE HIMSELF OR HERSELF FROM ANY VOTE UPON WHICH SUCH TRUSTEE, OR ANY MEMBER OF HIS OR HER IMMEDIATE FAMILY, HAS A MATERIAL FINANCIAL INTEREST. PRIOR TO EACH VOTE ON ORGANIZATION MATTERS, TRUSTEES ARE ASKED TO ABSTAIN AS APPROPRIATE BASED ON THE CONFLICT OF INTEREST POLICY. FORM 990, PART VI, SECTION B, LINE 15 THE ORGANIZATION HAS A COMPENSATION COMMITTEE FOR WHICH THE EXECUTIVE DIRECTOR'S COMPENSATION IS RESEARCHED AND AGREED UPON AND APPROVED. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION'S GOVERNING DOCUMENTS AND FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST. FORM 990, PART XII, LINE 2C: THE ORGANIZATION'S AUDIT COMMITTEE HAS RESPONSIBILITY FOR THE OVERSIGHT OF THE AUDIT OF ITS FINANCIAL STATEMENTS AND SELECTION OF THE INDEPENDENT AUDITOR, SUBJECT TO THE APPROVAL OF THE BOARD OF TRUSTEES. THIS RESPONSIBILITY IS UNCHANGED FROM THE PRIOR YEAR. MEDTECH INNOVATOR ASIA PACIFIC PTE LTD 51 GOLDHILL PLAZA 07-10/11 SINGAPORE SN COMPETITION FOR MEDICAL DEVICE, DIGITAL HEALTH, DIAGNOSTIC STARTUPS SN MEDTECH INNOVATOR 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 MEDTECH INNOVATOR ASIA PACIFIC PTE LTD D 449555 CASH ADVANCES